UK MHRA · August 18, 2026

MHRA sets out position on regulation of microbiome-based medicinal products

MHRA clarifies the UK licensing route for microbiome-based medicines to support developer access.

High obligation Sector Pharmaceuticals UK Pharmaceuticals

MHRA publishes position paper clarifying the UK licencing route for microbiome-based medicines, supporting developers to bring these innovative therapies to patients.

Read the official source ↗

Published by UK MHRA. HealthSignal links to the original document; the summary above is extracted from the source text.